COVID-19患者重症监护与器官支持相关死亡率:系统评价与荟萃分析
该研究系统检索PubMed、Embase和Cochrane数据库至2021年12月31日,纳入157项观察性研究、948,309例患者,采用随机效应模型汇总COVID-19患者住院、ICU、机械通气、肾脏替代治疗和ECMO相关病死率。结果显示院内死亡率25.9%(95%CI 24.0-27.8%),ICU死亡率37.3%(95%CI 34.6-40.1%),机械通气死亡率51.6%(95%CI 46.1-57.0%),肾脏替代治疗死亡率66.1%(95%CI 59.7-72.2%),ECMO死亡率58.0%(95%CI 46.9-68.9%)。机械通气相关死亡率(52.7% vs 31.3%,p=0.023)和肾脏替代治疗相关死亡率(66.7% vs 50.3%,p=0.003)从2020年到2021年下降。作者认为,尽管死亡率仍高且全球差异大,但机械通气支持患者的病死率自2020年以来显著改善。
要点
- COVID-19住院患者院内病死率为25.9%(95%CI 24.0-27.8%),ICU患者病死率为37.3%(95%CI 34.6-40.1%)。
- 接受机械通气的COVID-19患者病死率为51.6%(95%CI 46.1-57.0%),接受肾脏替代治疗者为66.1%(95%CI 59.7-72.2%),接受ECMO者为58.0%(95%CI 46.9-68.9%)。
- 机械通气相关病死率从2020年的52.7%(95%CI 47.5-58.0%)降至2021年的31.3%(95%CI 16.1-48.9%),p=0.023。
- 肾脏替代治疗相关病死率从2020年的66.7%(95%CI 60.1-73.0%)降至2021年的50.3%(95%CI 42.4-58.2%),p=0.003。
- 作者认为,尽管COVID-19重症患者死亡率仍高且全球差异大,但机械通气支持患者的病死率自2020年以来显著改善。
适用人群与场景
- 已发表同行评议的观察性研究,报告ICU、机械通气、肾脏替代治疗或ECMO相关死亡率,且纳入个体患者数≥100例。
研究设计与关键结果
- 研究类型:系统评价与荟萃分析;纳入157项观察性研究,共948,309例患者。
- 主要终点:院内病死率25.9%(95%CI 24.0-27.8%),ICU病死率37.3%(95%CI 34.6-40.1%),机械通气相关病死率51.6%(95%CI 46.1-57.0%),肾脏替代治疗相关病死率66.1%(95%CI 59.7-72.2%),ECMO相关病死率58.0%(95%CI 46.9-68.9%)。
- 时间趋势:机械通气相关病死率2020年52.7%(95%CI 47.5-58.0%)vs 2021年31.3%(95%CI 16.1-48.9%),p=0.023;肾脏替代治疗相关病死率2020年66.7%(95%CI 60.1-73.0%)vs 2021年50.3%(95%CI 42.4-58.2%),p=0.003。
- 敏感性分析:基于随访数据完整性、发表年份以及仅纳入高质量研究评估病死率。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尽管COVID-19重症患者死亡率仍高且全球差异大,但机械通气支持患者的病死率自2020年以来显著改善。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: To perform a systematic review and meta-analysis to generate estimates of mortality in patients with COVID-19 that required hospitalization, ICU admission, and organ support.
DATA SOURCES: A systematic search of PubMed, Embase, and the Cochrane databases was conducted up to December 31, 2021.
STUDY SELECTION: Previously peer-reviewed observational studies that reported ICU, mechanical ventilation (MV), renal replacement therapy (RRT) or extracorporeal membrane oxygenation (ECMO)-related mortality among greater than or equal to 100 individual patients.
DATA EXTRACTION: Random-effects meta-analysis was used to generate pooled estimates of case fatality rates (CFRs) for in-hospital, ICU, MV, RRT, and ECMO-related mortality. ICU-related mortality was additionally analyzed by the study country of origin. Sensitivity analyses of CFR were assessed based on completeness of follow-up data, by year, and when only studies judged to be of high quality were included.
DATA SYNTHESIS: One hundred fifty-seven studies evaluating 948,309 patients were included. The CFR for in-hospital mortality, ICU mortality, MV, RRT, and ECMO were 25.9% (95% CI: 24.0-27.8%), 37.3% (95% CI: 34.6-40.1%), 51.6% (95% CI: 46.1-57.0%), 66.1% (95% CI: 59.7-72.2%), and 58.0% (95% CI: 46.9-68.9%), respectively. MV (52.7%, 95% CI: 47.5-58.0% vs 31.3%, 95% CI: 16.1-48.9%; p = 0.023) and RRT-related mortality (66.7%, 95% CI: 60.1-73.0% vs 50.3%, 95% CI: 42.4-58.2%; p = 0.003) decreased from 2020 to 2021.
CONCLUSIONS: We present updated estimates of CFR for patients hospitalized and requiring intensive care for the management of COVID-19. Although mortality remain high and varies considerably worldwide, we found the CFR in patients supported with MV significantly improved since 2020.
参考来源
- Chandel A, Leazer S, Alcover KC, et al. Intensive Care and Organ Support Related Mortality in Patients With COVID-19: A Systematic Review and Meta-Analysis. Crit Care Explor. 2023. PMID: 36890875. doi:10.1097/CCE.0000000000000876
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。